Gilead Sciences

Live  

Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==

Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +RpSBGcmVl IGVCb29rIG ZvciBuZXcg dXNlcnM6ID xpPiJUaGUg Q2hlY2tsaX N0IFZhbHVl IEludmVzdG 9yIOKAlCBB IFNtYXJ0ZX IgV2F5IHRv IFBpY2sgU3 RvY2tzIjwv aT4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPC9w PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPCEt LQogICAgIC AgICAgICAg ICAgICAgIC AgICA8ZGl2 IHN0eWxlPS dtYXJnaW4t dG9wOiAxMn B4OyBmb250 LXNpemU6ID EzcHg7IGNv bG9yOiAjND Q0Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIG5vdy BhbmQgZ2V0 IG91ciBmcm VlIGVCb29r IAogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg PGI+VGhlIE NoZWNrbGlz dCBWYWx1ZS BJbnZlc3Rv ciDigJQgQS BTbWFydGVy IFdheSB0by BQaWNrIFN0 b2NrczwvYj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9kaX Y+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIC0tPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8IS0tCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxkaXYgc3 R5bGU9J21h cmdpbi10b3 A6IDE2cHg7 IGZvbnQtc2 l6ZTogMTRw eDsgY29sb3 I6ICM0NDQ7 IGZvbnQtZm FtaWx5OiAt YXBwbGUtc3 lzdGVtLCBC bGlua01hY1 N5c3RlbUZv bnQsIFNlZ2 9lIFVJLCBS b2JvdG8sIE hlbHZldGlj YSBOZXVlLC BzYW5zLXNl cmlmOyBsaW 5lLWhlaWdo dDogMS42Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BIYXZlIHlv dSBoZWFyZC BhYm91dCBv dXIgc2hvcn QgPHN0cm9u ZyBzdHlsZT 0nZm9udC13 ZWlnaHQ6ID YwMDsnPkRh aWx5IFZpZG VvIE5ld3Ns ZXR0ZXI8L3 N0cm9uZz4/ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICA8 YSBocmVmPS dodHRwczov L3d3dy5pbn NpZ2h0ZnVs dmFsdWUuY2 9tL25ld3Ns ZXR0ZXIucG hwJyB0YXJn ZXQ9J19ibG Fuaycgc3R5 bGU9J2NvbG 9yOiAjMDA3 QkZGOyB0ZX h0LWRlY29y YXRpb246IG 5vbmU7IGZv bnQtd2VpZ2 h0OiA1MDA7 IG1hcmdpbi 1sZWZ0OiA2 cHg7Jz4KIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC BGaW5kIG91 dCBtb3JlCi AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICA8L2 E+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDwvZG l2PgogICAg ICAgICAgIC AgICAgICAg ICAgICAtLT 4KICAgICAg ICAgICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICA8L2Rp dj4KICAgIC AgICAgICAg CiAgICAgIC AgCiAgICAg ICAgPHNwYW 4gY2xhc3M9 J2JsdXJyZW QtdGV4dCc+ CiAgICAgIC AgICAgIE1T NGdSMmxzWl cgRmtJRk5q YVdWdSBZMl Z6SUhkaGN5 IEJtYjNWdV pHVmsgSUds dUlERTVPRC BjZ1lua2dU V2xqIGFHRm xiQ0JTYVcg OXlaR0Z1TE NCaCBJRzFs WkdsallXIH dnWkc5amRH OXkgSUdaeW IyMGdUbSBW M0lGbHZjbX N1IElGUm9a U0JqYjIgMX dZVzU1SUhk aCBjeUJ1WV cxbFpDIEJo Wm5SbGNpQj AgYUdVZ1lt bGliRyBsal lXd2diR0Z1 IFpDQnZaaU JIYVcgeGxZ V1FzSUhkby BhV05vSUhk aGN5IEJyYm 05M2JpQm0g YjNJZ2FYUn pJRyBobFlX eHBibWNnIG NISnZjR1Z5 ZEcgbGxjeT Q4WW5JKyBN aTRnUjJsc1 pXIEZrSUZO amFXVnUgWT JWeklHbHpJ RyBFZ1ltbH ZjR2hoIGNt MWhZMlYxZE cgbGpZV3dn WTI5dCBjR0 Z1ZVNCMGFH IEYwSUdadl kzVnogWlhN Z2IyNGdaRy BWMlpXeHZj R2x1IFp5Qm hibVFnWTIg OXRiV1Z5WT JsaCBiR2w2 YVc1bklIIF JvWlhKaGNH bGwgY3lCbW IzSWdiRyBs bVpTMTBhSE psIFlYUmxi bWx1WnkgQm thWE5sWVhO bCBjeXdnZD JsMGFDIEJo SUhCaGNuUn AgWTNWc1lY SWdabSA5am RYTWdiMjRn IFNFbFdMME ZKUkYgTXNJ R2hsY0dGMC BhWFJwY3lC Q0lHIEZ1Wk NCRExDQnMg YVhabGNpQm thWCBObFlY TmxjeXdnIG IyNWpiMnh2 WjMga3NJR0 Z1WkNCeSBa WE53YVhKaG RHIDl5ZVNC a2FYTmwgWV hObGN5NDhZ biBJK015NG dWR2hsIElH TnZiWEJoYm 4gbmlnSmx6 SUdacCBjbk 4wSUcxaGFt IDl5SUdKeV pXRnIgZEdo eWIzVm5hQy BCallXMWxJ R2x1IElERT VPVFlnZDIg bDBhQ0IwYU dVZyBZWEJ3 Y205MllXIH dnYjJZZ2RH aGwgYVhJZ1 NFbFdJSCBS eVpXRjBiV1 Z1IGRDQmtj blZuTEMgQl dhWEpsWVdR cyBJSGRvYV dOb0lIIGRo Y3lCMGFHVW cgWm1seWMz UWdkSCBKbF lYUnRaVzUw IElIUnZJSF JoY20gZGxk Q0JoYmlCbC BibnA1YldV Z1kyIEZzYk dWa0lISmwg ZG1WeWMyVW dkSCBKaGJu TmpjbWx3IG RHRnpaU0Iw YUcgRjBJR2 x6SUdWeiBj MlZ1ZEdsaG JDIEJtYjNJ Z2RHaGwgSU hKbGNHeHBZ MiBGMGFXOX VJRzltIElI Um9aU0JJU1 YgWWdkbWx5 ZFhNdSBQR0 p5UGpRdUlF IGx1SURJd0 1URXMgSUVk cGJHVmhaQy BCVFkybGxi bU5sIGN5Qm hZM0YxYVgg SmxaQ0IwYU dVZyBZbWx2 Y0doaGNtID FoWTJWMWRH bGogWVd3Z1 kyOXRjRyBG dWVTd2dVR2 hoIGNtMWhj M05sZEMgd2 dabTl5SUNR eCBNU0JpYV d4c2FXIDl1 TGlCVWFHbH ogSUdGamNY VnBjMiBsMG FXOXVJR0p5 IGIzVm5hSF FnUjIgbHNa V0ZrSUhSby BaU0JpYkc5 amEyIEoxYz NSbGNpQmsg Y25WbkxDQl RiMyBaaGJH UnBMQ0IzIG FHbGphQ0J5 WlggWnZiSF YwYVc5dSBh WHBsWkNCMG FHIFVnZEhK bFlYUnQgWl c1MElHWnZj aSBCb1pYQm hkR2wwIGFY TWdReTQ4WW 4gSStOUzRn UjJscyBaV0 ZrSUZOamFX IFZ1WTJWek lHaGggY3lC aElITjBjbS A5dVp5Qmpi MjF0IGFYUn RaVzUwSUgg UnZJR052Y2 5CdiBjbUYw WlNCemIyIE 5wWVd3Z2Nt VnogY0c5dW MybGlhVyB4 cGRIa3VJRl JvIFpTQmpi MjF3WVcgNT VJR2hoY3lC ayBaWFpsYk c5d1pXIFFn WVc0Z1lXTm ogWlhOeklI QnliMiBkeV lXMGdkRzhn IGNISnZkbW xrWlMgQnBk SE1nYldWay BhV05oZEds dmJuIE1nZE c4Z2JHOTMg TFdsdVkyOX RaUyBCamIz VnVkSEpwIF pYTWdZWFFn WkcgbHpZMj kxYm5SbCBa Q0J3Y21sal pYIE1zSUdG dVpDQmggYk hOdklHaGhj eSBCd2NtOW 5jbUZ0IGN5 QjBieUJ6ZF ggQndiM0ow SUdOdiBiVz ExYm1sMGVT IEJoYm1RZ1 pXUjEgWTJG MGFXOXVZVy B3Z2FXNXBk R2xoIGRHbD JaWE11UEcg SnlQall1SU VsdSBJREl3 TWpBc0lFIG RwYkdWaFpD QlQgWTJsbG JtTmxjeSBC dFlXUmxJR2 hsIFlXUnNh VzVsY3kgQj NhWFJvSUds MCBjeUJsZU hCbGNtIGx0 Wlc1MFlXd2 cgWkhKMVp5 d2djbSBWdF pHVnphWFpw IGNpd2dkMm hwWTIgZ2dj Mmh2ZDJWay BJSEJ5YjIx cGMyIGx1Wn lCeVpYTjEg YkhSeklHbH VJSCBSeVpX RjBhVzVuIE lFTlBWa2xF TFQgRTVJSE JoZEdsbCBi blJ6TGlCVW FHIFVnWkhK MVp5QnkgWl dObGFYWmxa QyBCbGJXVn laMlZ1IFkz a2dkWE5sSU cgRjFkR2h2 Y21sNiBZWF JwYjI0Z1pu IEp2YlNCMG FHVWcgUmtS QklHRnVaQy BCb1lYTWdj Mmx1IFkyVW dZbVZsYmkg QmthWE4wY2 1saSBkWFJs WkNCaGNtID kxYm1RZ2RH aGwgSUhkdm NteGtMaiB4 aWNqNDNMaU JIIGFXeGxZ V1FnVTIgTn BaVzVqWlhN ZyBhR0Z6SU dFZ1pHIGwy WlhKelpTQj MgYjNKclpt OXlZMiBVc0 lIZHBkR2dn IFpXMXdiRz k1WlcgVnpJ R1p5YjIwZy BiM1psY2lB Mk5TIEJqYj NWdWRISnAg WlhNZ1lXNW tJRyBFZ2JH VmhaR1Z5IG MyaHBjQ0Iw WlcgRnRJRz FoWkdVZyBk WEFnYjJZZ0 5EIGNsSUhk dmJXVnUgTG p4aWNqNDRM aSBCVWFHVW dZMjl0IGNH RnVlU0JvWV ggTWdZU0J6 ZEhKdiBibW NnWjJ4dllt IEZzSUhCeV pYTmwgYm1O bExDQjNhWC BSb0lHOXda WEpoIGRHbH Zibk1nYVcg NGdUbTl5ZE dnZyBRVzFs Y21sallTIH dnUlhWeWIz QmwgTENCS1 lYQmhiaSB3 Z1lXNWtJRU Z6IGFXRWdV R0ZqYVcgWn BZeTQ4WW5J KyBPUzRnUj Jsc1pXIEZr SUZOamFXVn UgWTJWeklH aGhjeSBCaV pXVnVJRzVo IGJXVmtJRz l1WlMgQnZa aUIwYUdVZy BWMjl5YkdU aWdKIGx6SU UxdmMzUWcg UVdSdGFYSm xaQyBCRGIy MXdZVzVwIF pYTWdZbmtn Um0gOXlkSF Z1WlNCTiBZ V2RoZW1sdV pTIEJtYjNJ Z1ptOTEgY2 lCamIyNXpa VyBOMWRHbD JaU0I1IFpX RnljeUFvTW ogQXhOeTB5 TURJdyBLUz Q4WW5JK01U IEF1SUVkcG JHVmggWkNC VFkybGxibS BObGN5QnBj eUJqIGIyMX RhWFIwWlcg UWdkRzhnYz NWeiBkR0Zw Ym1GaWFXIH hwZEhrZ1lX NWsgSUdoaG N5QnpaWCBR Z2RHRnlaMl YwIGN5QjBi eUJ5WlcgUj FZMlVnZEdo bCBhWElnWl c1MmFYIEp2 Ym0xbGJuUm ggYkNCcGJY QmhZMyBRc0 lHbHVZMngx IFpHbHVaeU JoSUcgZHZZ V3dnZEc4Zy BjMjkxY21O bElEIEV3TU NVZ2NtVnUg WlhkaFlteG xJRyBWc1pX TjBjbWxqIG FYUjVJR0o1 SUQgSXdNak FnWVc1ayBJ SEpsWkhWal pTIEJuY21W bGJtaHYgZF hObElHZGhj eSBCbGJXbH pjMmx2IGJu TWdZbmtnTW ogVWxJR0o1 SURJdyBNak l1CiAgICAg ICAgPC9zcG FuPgogICAg ICAgIAogIC AgICAgIA==
See Company Q&A